News & Updates

Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates

08/24/2021

Excerpt from the Press Release: PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive data demonstrating the efficacy of multiple filovirus vaccine candidates in NHPs, including thermostabilized multivalent vaccines…

Read More

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

08/24/2021

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical development.…

Read More

Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics

08/24/2021

Excerpt from the Press Release: SUNNYVALE, Calif. & PITTSBURGH, Pa.–(BUSINESS WIRE)–Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras…

Read More

Gritstone secures CEPI funding to test Covid vaccine; first focus is South Africa

08/23/2021

Excerpt from the Press Release: Gritstone bio is developing Covid-19 vaccines that use self-amplifying messenger RNA, which is intended to further boost the immune response compared to mRNA alone. The company also says its vaccine candidates may be able to protect against variants of the novel coronavirus. As coronavirus variants continue to fuel the ongoing…

Read More

Qualigen calls it quits on COVID antiviral after pouring millions into R&D

08/23/2021

Excerpt from the Press Release: The FDA wanted a couple more clinical studies for Qualigen’s investigational COVID-19 antiviral before human testing, but the biotech is calling it quits instead. Shares of the company plunged nearly 20% to $1.34 as the markets opened Tuesday, underscoring the risk that small companies take on when trying to jump…

Read More

Shorla Pharma Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment

08/23/2021

Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 17, 2021 /PRNewswire/ — Shorla Pharma (‘Shorla’), a specialty pharmaceutical company  and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support the launch and commercialization of Shorla’s oncology portfolio. The new partnership will initially focus on SH-111, an oncology drug designed…

Read More

BlackBerry QNX Cybersecurity Vulnerabilities May Affect Drug Manufacturing Equipment

08/20/2021

Excerpt from the Press Release: The U.S. Food and Drug Administration is informing patients, health care providers, and manufacturers about cybersecurity vulnerabilities with a “real-time operating system (RTOS)” designed by QNX and owned by BlackBerry. These vulnerabilities may introduce risks for certain medical devices and drug manufacturing equipment. FDA is not aware of any confirmed adverse events related to these vulnerabilities. Manufacturers…

Read More

To prepare for the next big health crisis, Canada needs to strengthen its biotech sector

08/20/2021

Excerpt from the Press Release: Subsidies, tax breaks and funding will keep momentum going in Canada’s promising biomanufacturing industry. Why weren’t we better prepared? The frantic search for gloves and masks, then ventilators and life-saving drugs, and then the scramble to ramp up testing, slow the deaths in long-term care and deploy vaccines — the…

Read More

Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder

08/19/2021

Excerpt from the Press Release: BRISBANE, Calif. – August 10, 2021 – Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity…

Read More

Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program

08/19/2021

Excerpt from the Press Release: SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a presentation on its corporate website to provide an overview of Sorrento’s proprietary mRNA vaccine development program for COVID-19.…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives